ReviewCancers2014
Mutational analysis of merkel cell carcinoma.
Review in Cancers, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies.International journal of molecular sciences · 2024Review
- Genomic Alterations and Tumor Mutation Burden in Merkel Cell Carcinoma.JAMA network open · 2023Article
- Therapeutic Potential of 5'-Methylschweinfurthin G in Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma.Viruses · 2022Article
- Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies.International journal of molecular sciences · 2021Review
- Virus-Driven Carcinogenesis.Cancers · 2021Review
- Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs.Molecules (Basel, Switzerland) · 2019Review
- Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC.Cancer immunology, immunotherapy : CII · 2018Review
- Merkel cell carcinoma masquerading as cellulitis: a case report and review of the literature.Current oncology (Toronto, Ont.) · 2018Article
- Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.Reviews in endocrine & metabolic disorders · 2017Review
- Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNAClinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Aberrant expression of ALK and EZH2 in Merkel cell carcinoma.BMC cancer · 2017Article
- Prognostic relevance of high atonal homolog-1 expression in Merkel cell carcinoma.Journal of cancer research and clinical oncology · 2017Article
- Merkel cell polyomavirus and cutaneous Merkel cell carcinoma.Future science OA · 2016Article
- Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics.Oncotarget · 2016Article
- Effect of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against human Merkel cell carcinoma MKL-1 cells.Oncology letters · 2015Article
- The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma.Cancer research · 2015Article
- Merkel Cell Carcinoma with a Suppressor of Fused (SUFU) Mutation: Case Report and Potential Therapeutic Implications.Dermatology and therapy · 2015Article
- Challenges of Treating Recurrent Merkel Cell Carcinoma in the Rural US: A Case Report.The Journal of clinical and aesthetic dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy that is associated with a poor prognosis. The pathogenesis of MCC is not well understood, and despite a recent plethora of mutational analyses, we have yet to find a set of signature mutations implicated in the majority of cases. Mutations, including TP53, Retinoblastoma and PIK3CA, have been documented in subsets of patients. Other mechanisms are also likely at play, including infection with the Merkel cell polyomavirus in a subset of patients, dysregulated immune surveillance, epigenetic alterations, aberrant protein expression, posttranslational modifications and microRNAs. In this review, we summarize what is known about MCC genetic mutations and chromosomal abnormalities, and their clinical significance. We also examine aberrant protein function and microRNA expression, and discuss the therapeutic and prognostic implications of these findings. Multiple clinical trials designed to selectively target overexpressed oncogenes in MCC are currently underway, though most are still in early phases. As we accumulate more molecular data on MCC, we will be better able to understand its pathogenic mechanisms, develop libraries of targeted therapies, and define molecular prognostic signatures to enhance our clinicopathologic knowledge.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.